ALLO
Allogene Therapeutics, Inc.
There isn't enough reported data to score ALLO yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ALLO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ALLO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ALLO PE Valuation
ALLO has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ALLO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ALLO's losses to shrink, with revenue growing.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ALLO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.63 | +$0.34 |
| Q2 2026 | -$0.67 | +$0.43 |
| Q1 2026 | -$0.77 | +$0.45 |
| Q4 2025 | -$0.87 | +$0.45 |
| Q3 2025 | -$0.97 | +$0.57 |
| Q2 2025 | -$1.10 | +$0.49 |
| Q1 2025 | -$1.22 | +$0.55 |
| Q4 2024 | -$1.32 | +$0.75 |
ALLO has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ALLO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2024 | $22K | -58% |
| Q4 2023 | $21K | -55% |
| Q3 2023 | $43K | -12% |
| Q2 2023 | $44K | -49% |
| Q1 2023 | $52K | -15% |
| Q4 2022 | $47K | -7.8% |
| Q3 2022 | $49K | 0% |
| Q2 2022 | $86K | +95% |
ALLO's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1011% | N/A |
| Q1 2024 | -315927% | -125408 points |
| Q4 2023 | -405281% | -200230 points |
| Q3 2023 | -146453% | +21891 points |
| Q2 2023 | -182995% | -93933 points |
| Q1 2023 | -190519% | -59385 points |
| Q4 2022 | -205051% | -60163 points |
| Q3 2022 | -168345% | -9835 points |
ALLO's operating margin was −1011% last quarter, up 181984 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ALLO on profitability, with a higher operating margin.
ALLO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$36.1M | -$6.2M |
| Q2 2026 | -$32.1M | +$6.9M |
| Q1 2026 | -$12.9M | +$40.1M |
| Q4 2025 | -$27.6M | +$9.4M |
| Q3 2025 | -$29.9M | +$14.6M |
| Q2 2025 | -$39.1M | +$24.5M |
| Q1 2025 | -$53M | +$2.9M |
| Q4 2024 | -$37M | +$16.9M |
ALLO has burned cash in almost every quarter: −$109M over the past year, against −$159M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ALLO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ALLO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.2% | +17.2M shares |
| 1 year | +56% | +124M shares |
| 3 years | +106% | +178M shares |
| 5 years | +153% | +209M shares |
| Available history | +242% | +245M shares |
ALLO has 346M diluted shares, up 56% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ALLO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ALLO Net Leverage
ALLO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ALLO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.2 | Oversold |
| Stochastic | 2.4 | Oversold |
ALLO's weekly RSI is 24 (oversold) and its Stochastic is 2 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ALLO PE vs Healthcare Sector
ALLO has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ALLO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.28 | 35% below |
| 20 week MA | $1.67 | 50% below |
| 50 week MA | $1.86 | 55% below |
| 100 week MA | $1.66 | 50% below |
| 200 week MA | $2.76 | 70% below |
ALLO is in a downtrend: it's below all five of its weekly moving averages, and 70% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ALLO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.3 | $27.3 | +3.8% |
| 2021 | $27.3 | $15.7 | -43% |
| 2022 | $15.7 | $5.96 | -62% |
| 2023 | $5.96 | $3.21 | -46% |
| 2024 | $3.21 | $2.19 | -32% |
| 2025 | $2.19 | $1.38 | -37% |
| 2026 YTD | $1.38 | $0.83 | -40% |
ALLO has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.